Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

Bausch Health and YUN extend their microbiome-based skincare collaboration into Mexico and several new EMEA markets, with Kazakhstan slated for October 2026.

Rhea-AI Summary

Bausch Health (BHC) and Belgian skincare company YUN are expanding their strategic collaboration to Mexico and additional EMEA markets following a 2025 launch in Poland.

In Poland, Bausch Health broadened its dermatology portfolio to include YUN's eczema-prone skincare solutions alongside existing acne-prone products. Geographic rollout now covers YUN's acne- and eczema-prone skincare in the Czech Republic, Slovakia, Ukraine and Bulgaria, with YUN skincare also introduced in Mexico. The companies expect the next launch phase in Kazakhstan in October 2026, aiming to increase access to science-led, microbiome-friendly probiotherapeutical skincare solutions.

Positive

• Dermatology portfolio expanded in Poland with YUN eczema-prone skincare added to existing acne-prone products
• Geographic presence broadened with launches in Czech Republic, Slovakia, Ukraine, Bulgaria and Mexico
• Further rollout planned in Kazakhstan in October 2026, extending YUN Probiotherapy reach

Negative

• None.

Market Context

-2.96% pre-headline price movement placed BHC below its prior close as the collaboration expanded; o...

Analysis

-2.96% pre-headline price movement placed BHC below its prior close as the collaboration expanded; only one tracked peer was down, so the data did not show broad sector alignment.

Key Figures

Kazakhstan rollout: October 2026

Kazakhstan rollout

October 2026

Expected continuation of the skincare expansion

Key Terms

microbiome, probiotics, pre- and postbiotics

3 terms

microbiome medical

"science-led, microbiome-friendly skincare solutions"

Microbiome is the community of tiny living organisms—bacteria, viruses, fungi and their genes—that live in a particular place, like the gut, skin or soil; think of it as a neighborhood of microscopic life that affects how that environment works. Investors care because changes or products that target the microbiome can alter health outcomes, crop yields or consumer product performance, creating new markets, regulatory risks and potential shifts in revenue for companies.

probiotics medical

"stable use of live probiotics in skincare formulations"

Live microorganisms, often called "good" bacteria, that are added to foods or supplements and are intended to support health when taken in sufficient amounts; think of them as friendly tenants that help keep your gut environment balanced. For investors, probiotics matter because consumer demand, scientific evidence, and regulatory rules determine market size, product labeling, manufacturing standards and potential legal or reimbursement risks, all of which affect sales and company valuations.

pre- and postbiotics medical

"combining live probiotics with pre- and postbiotics"

Prebiotics are non-digestible food ingredients, usually fibers or oligosaccharides, that feed and promote growth of beneficial gut microbes; postbiotics are metabolic byproducts or compounds produced by those microbes, such as short-chain fatty acids or proteins, that can have direct effects on the host. Investors track these because they are distinct product categories in health, nutrition, and therapeutic markets, shaping regulatory pathways, claims, manufacturing needs and potential revenue streams; think of prebiotics as fertilizer for a garden and postbiotics as the nutrients the plants produce.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine, Bulgaria and Kazakhstan.

LAVAL, QC, Sept. 8, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering probiotherapeutical skincare products, announced the continued expansion of their strategic collaboration in Mexico and across additional EMEA markets following the 2025 launch in Poland.

The expansion includes both portfolio and geographic growth in recent months. In Poland, Bausch Health expanded its dermatology portfolio to include YUN's eczema-prone skincare solutions, building on last year's launch of YUN's probiotic-based skincare solutions for acne-prone skin. Geographic expansion has included launches of YUN's acne- and eczema-prone skincare solutions in the Czech Republic, Slovakia, Ukraine, Bulgaria, along with the introduction of YUN's skincare solutions in Mexico. The rollout is expected to continue in Kazakhstan in October 2026. This next phase of the collaboration reflects both companies' shared ambition to expand access to science-led, microbiome-friendly skincare solutions across EMEA and select international growth markets.

"Following our collaboration in Poland, YUN has entered and is continuing to enter additional markets as part of our broader EMEA growth strategy," said Cees Heiman, Senior Vice President, Europe & Canada, Bausch Health. "These launches reflect our commitment to bringing differentiated, science-based healthcare and skincare solutions to patients and consumers across the region. EMEA remains a strategically important geography for Bausch Health, and we see strong potential for YUN's microbiome-focused approach in markets such as Ukraine, Bulgaria, Czech Republic, Slovakia and Kazakhstan."

"Bringing YUN to Mexico expands our dermatology portfolio with skincare solutions grounded in microbiome science," said Fernando Zarate, Vice President, Latin America, Bausch Health. "This launch reflects our focus on identifying differentiated products that address evolving skincare needs and broaden access to innovative dermatology offerings in the Mexican market."

"We are proud to deepen our collaboration with Bausch Health and to see YUN entering additional international markets," said Tom Verlinden, CEO and Founder of YUN. "Our mission is to harness microbiome science through YUN Probiotherapy™, creating effective, natural and scientifically grounded solutions that respect the body's own balance. Expanding into Ukraine, Bulgaria, Czech Republic, Slovakia, Kazakhstan, and Mexico allows us to bring that mission to more people together with a partner that combines scale, credibility and strong regional execution."

YUN has developed YUN Probiotherapy™, a proprietary microbiome technology platform enabling the stable use of live probiotics in skincare formulations designed to support the skin's natural ecosystem. Through this expanded partnership, Bausch Health and YUN are strengthening the brand's presence across selected EMEA markets and Mexico while increasing access to innovative probiotherapeutical skincare solutions.

About YUN

YUN is a Belgian biotech company pioneering a new approach to everyday care through microbiome science. Founded in 2016, YUN developed the patented YUN Probiotherapy™ technology platform, combining live probiotics with pre- and postbiotics and microbiome-friendly formulations designed to respect and support the skin's natural microbiome. With innovations across dermatological, oral, baby, intimate, and ear care, YUN delivers science- and quality-driven, nature-powered solutions for patients and consumers, today and for generations to come. For more info about YUN, visit our site www.yun-probiotherapy.com or follow us on Linkedin.

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

Forward-looking Statements

This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

BHC-PRODUCTS

Investor Contact:
Garen Sarafian 
ir@bauschhealth.com
(877) 281-6642 (toll free) 

Media Contact: 
Katie Savastano
corporate.communications@bauschhealth.com
(908) 569-3692

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-and-yun-announce-expansion-to-mexico-and-across-additional-emea-markets-302866505.html

SOURCE Bausch Health Companies Inc.

FAQ

Which specific YUN skincare solutions are included in the expanded Bausch Health collaboration?

The expansion includes YUN's probiotic-based skincare solutions for acne-prone and eczema-prone skin. In Poland, Bausch Health added eczema-prone skincare solutions to the prior launch of acne-prone products, and these acne- and eczema-prone ranges are part of the rollout in several new EMEA markets.

Which new EMEA and international markets are being added for YUN products?

New markets referenced in the expansion include the Czech Republic, Slovakia, Ukraine, and Bulgaria, where YUN's acne- and eczema-prone skincare solutions have launched. YUN skincare has also been introduced in Mexico, and a rollout is expected in Kazakhstan in October 2026.

What is YUN Probiotherapy and how is it described in the announcement?

YUN Probiotherapy™ is described as a proprietary microbiome technology platform that enables the stable use of live probiotics in skincare formulations designed to support the skin's natural ecosystem. YUN uses this patented platform by combining live probiotics with pre- and postbiotics and microbiome-friendly formulations intended to respect and support the skin's natural microbiome.

How do Bausch Health and YUN describe the purpose of this expanded collaboration?

The companies state that this phase of the collaboration reflects a shared ambition to expand access to science-led, microbiome-friendly skincare solutions across EMEA and selected international growth markets. They also indicate that the partnership is intended to strengthen YUN's brand presence in selected EMEA markets and Mexico while increasing access to innovative probiotherapeutical skincare solutions.